Decibel Cannabis Past Earnings Performance
Past criteria checks 0/6
Decibel Cannabis has been growing earnings at an average annual rate of 23.5%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 48.7% per year.
Key information
23.5%
Earnings growth rate
52.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 48.7% |
| Return on equity | -2.4% |
| Net Margin | -0.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Decibel Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 112 | -1 | 34 | 0 |
| 31 Dec 23 | 116 | -2 | 35 | 0 |
| 30 Sep 23 | 112 | -4 | 30 | 0 |
| 30 Jun 23 | 100 | 1 | 27 | 0 |
| 31 Mar 23 | 88 | -1 | 25 | 0 |
| 31 Dec 22 | 79 | -4 | 23 | 0 |
| 30 Sep 22 | 68 | -1 | 21 | 0 |
| 30 Jun 22 | 63 | -7 | 20 | 0 |
| 31 Mar 22 | 56 | -5 | 20 | 0 |
| 31 Dec 21 | 52 | 2 | 18 | 0 |
| 30 Sep 21 | 50 | -1 | 17 | 0 |
| 30 Jun 21 | 44 | -1 | 17 | 0 |
| 31 Mar 21 | 38 | -3 | 14 | 0 |
| 31 Dec 20 | 30 | -9 | 15 | 0 |
| 30 Sep 20 | 20 | -14 | 13 | 0 |
| 30 Jun 20 | 15 | -13 | 11 | 0 |
| 31 Mar 20 | 11 | -9 | 9 | 0 |
| 31 Dec 19 | 6 | -7 | 5 | 0 |
| 30 Sep 19 | 5 | -1 | 3 | 0 |
| 30 Jun 19 | 2 | -1 | 2 | 0 |
| 31 Mar 19 | 1 | -3 | 2 | 0 |
| 31 Dec 18 | 0 | -3 | 2 | 0 |
Quality Earnings: DBCC.F is currently unprofitable.
Growing Profit Margin: DBCC.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DBCC.F is unprofitable, but has reduced losses over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare DBCC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DBCC.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: DBCC.F has a negative Return on Equity (-2.41%), as it is currently unprofitable.